[
  {
    "ts": null,
    "headline": "Regeneron Upgraded as AbbVie Catches Policy Heat",
    "summary": "Citi sees MFN pricing and PBM threats as manageable for REGN but riskier for ABBV",
    "url": "https://finnhub.io/api/news?id=08a6e49d62891654fec8e67d25d9c0070472bb525cb9b0f0e9ffdf6d9a5fe079",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747263764,
      "headline": "Regeneron Upgraded as AbbVie Catches Policy Heat",
      "id": 134460780,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Citi sees MFN pricing and PBM threats as manageable for REGN but riskier for ABBV",
      "url": "https://finnhub.io/api/news?id=08a6e49d62891654fec8e67d25d9c0070472bb525cb9b0f0e9ffdf6d9a5fe079"
    }
  },
  {
    "ts": null,
    "headline": "FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases",
    "summary": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to AbbVie Inc.’s (NYSE:ABBV) Emrelis (telisotuzumab vedotin-tllv) for adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy. High c-Met protein overexpression is defined as ≥ 50% of tumor cells with strong (3+) staining as determined by an FDA-approved test. This indication is approved based o",
    "url": "https://finnhub.io/api/news?id=3765ad4cc0068856bbcac9491e42c3ab8084481753ffe26af0f234ae64fbd6d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747250705,
      "headline": "FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases",
      "id": 134460781,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to AbbVie Inc.’s (NYSE:ABBV) Emrelis (telisotuzumab vedotin-tllv) for adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy. High c-Met protein overexpression is defined as ≥ 50% of tumor cells with strong (3+) staining as determined by an FDA-approved test. This indication is approved based o",
      "url": "https://finnhub.io/api/news?id=3765ad4cc0068856bbcac9491e42c3ab8084481753ffe26af0f234ae64fbd6d7"
    }
  },
  {
    "ts": null,
    "headline": "Citigroup Downgrades AbbVie (ABBV)",
    "summary": "Citigroup Downgrades AbbVie (ABBV)",
    "url": "https://finnhub.io/api/news?id=5039fc79b2ca4fac1077536aab1aeae033ad816155dd4f10f2a09405f765b4d6",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747244036,
      "headline": "Citigroup Downgrades AbbVie (ABBV)",
      "id": 134443244,
      "image": "",
      "related": "ABBV",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5039fc79b2ca4fac1077536aab1aeae033ad816155dd4f10f2a09405f765b4d6"
    }
  },
  {
    "ts": null,
    "headline": "US FDA approves AbbVie's drug for a type of lung cancer",
    "summary": "The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates, which act as \"guided-missiles\" that target only cancer cells while sparing healthy cells, unlike conventional chemotherapy.  Emrelis was approved for a type of non-squamous non-small cell lung cancer (NSCLC), for which patients were previously treated with other drugs but the disease still spread to other parts of the body.  These patients also showed an excess of c-Met protein, which is known to trigger tumor development and resistance to certain therapies.",
    "url": "https://finnhub.io/api/news?id=e81d41c935c909cb436d379f876d47a100f46973dbbcf94701945bc20cec2136",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747243395,
      "headline": "US FDA approves AbbVie's drug for a type of lung cancer",
      "id": 134460782,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates, which act as \"guided-missiles\" that target only cancer cells while sparing healthy cells, unlike conventional chemotherapy.  Emrelis was approved for a type of non-squamous non-small cell lung cancer (NSCLC), for which patients were previously treated with other drugs but the disease still spread to other parts of the body.  These patients also showed an excess of c-Met protein, which is known to trigger tumor development and resistance to certain therapies.",
      "url": "https://finnhub.io/api/news?id=e81d41c935c909cb436d379f876d47a100f46973dbbcf94701945bc20cec2136"
    }
  },
  {
    "ts": null,
    "headline": "U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression",
    "summary": "AbbVie (NYSE: ABBV) today announced that EMRELIS™ (telisotuzumab vedotin-tllv) has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy. High c-Met protein overexpression is defined as ≥ 50% of tumor cells with strong (3+) staining as determined by an FDA-approved",
    "url": "https://finnhub.io/api/news?id=4f83df20511a077215ce6dcc265f65aebf33639ba46a8f90555cb4e765547d2b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747242540,
      "headline": "U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression",
      "id": 134460783,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced that EMRELIS™ (telisotuzumab vedotin-tllv) has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy. High c-Met protein overexpression is defined as ≥ 50% of tumor cells with strong (3+) staining as determined by an FDA-approved",
      "url": "https://finnhub.io/api/news?id=4f83df20511a077215ce6dcc265f65aebf33639ba46a8f90555cb4e765547d2b"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer",
    "summary": "Evaluate AbbVie Inc. vs. Pfizer Inc. amidst tariff disputes and drug pricing policies. Click for our comparison of ABBV and PFE stock and which one we prefer.",
    "url": "https://finnhub.io/api/news?id=387ff3f6523a6f26d030160f3e4d6f215b340a2df1c552ebbe9e52038422b53d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747240576,
      "headline": "Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer",
      "id": 134454257,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1886168190/image_1886168190.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Evaluate AbbVie Inc. vs. Pfizer Inc. amidst tariff disputes and drug pricing policies. Click for our comparison of ABBV and PFE stock and which one we prefer.",
      "url": "https://finnhub.io/api/news?id=387ff3f6523a6f26d030160f3e4d6f215b340a2df1c552ebbe9e52038422b53d"
    }
  },
  {
    "ts": null,
    "headline": "BlackRock Health Sciences Opportunities Fund Q1 2025 Commentary",
    "summary": "BlackRock Health Sciences Opportunities Fund posted returns of 3.66% (Institutional shares) and 3.60% (Investor A shares, without sales charge) for the first quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=a09fa1031198fe3423a5318e0d47459c521efb03ae4196a089069f85176f0e54",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747237080,
      "headline": "BlackRock Health Sciences Opportunities Fund Q1 2025 Commentary",
      "id": 134453013,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183355336/image_183355336.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "BlackRock Health Sciences Opportunities Fund posted returns of 3.66% (Institutional shares) and 3.60% (Investor A shares, without sales charge) for the first quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=a09fa1031198fe3423a5318e0d47459c521efb03ae4196a089069f85176f0e54"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Presents at BofA Securities 2025 Healthcare Conference (Transcript)",
    "summary": "AbbVie Inc. (NYSE:ABBV) BofA Securities 2025 Healthcare Conference May 14, 2025 1:00 PM ETCompany ParticipantsJeff Stewart - EVP and Chief Commercialization...",
    "url": "https://finnhub.io/api/news?id=67f9fa01bd07c92a71d0f1c2fa04e3a088ba62481950854b051b0ca576ff0860",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747235441,
      "headline": "AbbVie Inc. (ABBV) Presents at BofA Securities 2025 Healthcare Conference (Transcript)",
      "id": 134449185,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. (NYSE:ABBV) BofA Securities 2025 Healthcare Conference May 14, 2025 1:00 PM ETCompany ParticipantsJeff Stewart - EVP and Chief Commercialization...",
      "url": "https://finnhub.io/api/news?id=67f9fa01bd07c92a71d0f1c2fa04e3a088ba62481950854b051b0ca576ff0860"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV): Among the Best Dividend Growth Stocks with High Yields",
    "summary": "We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend growth stocks. Dividend-paying stocks have been gaining popularity among investors due to their long-term advantages. According to Jeremy Zirin, who […]",
    "url": "https://finnhub.io/api/news?id=dca71f39c7ea1861f4db0f4aa0d297620b1e4cd9a29c7cc7ff03a4184ecae242",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747233649,
      "headline": "AbbVie Inc. (ABBV): Among the Best Dividend Growth Stocks with High Yields",
      "id": 134460784,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend growth stocks. Dividend-paying stocks have been gaining popularity among investors due to their long-term advantages. According to Jeremy Zirin, who […]",
      "url": "https://finnhub.io/api/news?id=dca71f39c7ea1861f4db0f4aa0d297620b1e4cd9a29c7cc7ff03a4184ecae242"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.",
    "summary": "Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.",
    "url": "https://finnhub.io/api/news?id=f8c1cfa894866d555966a99ef25ad5025cc94366a9494d7fb939373c94d2bfdc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747232640,
      "headline": "Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.",
      "id": 134460785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.",
      "url": "https://finnhub.io/api/news?id=f8c1cfa894866d555966a99ef25ad5025cc94366a9494d7fb939373c94d2bfdc"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie, Merck cut to Neutral at Citi",
    "summary": "Investing.com -- Citi downgraded both AbbVie (NYSE:ABBV) and Merck (NSE:PROR) to Neutral in separate notes Wednesday, citing long-term growth concerns and late-stage pipeline limitations as headwinds for the pharmaceutical giants.",
    "url": "https://finnhub.io/api/news?id=1a0e50f4030555ce7b3f45c81c6f7078d973f8a24035ea2b237574490fc542ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747230854,
      "headline": "AbbVie, Merck cut to Neutral at Citi",
      "id": 134460786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investing.com -- Citi downgraded both AbbVie (NYSE:ABBV) and Merck (NSE:PROR) to Neutral in separate notes Wednesday, citing long-term growth concerns and late-stage pipeline limitations as headwinds for the pharmaceutical giants.",
      "url": "https://finnhub.io/api/news?id=1a0e50f4030555ce7b3f45c81c6f7078d973f8a24035ea2b237574490fc542ca"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=6254788561d9d8281c349457b4313591f319baf9afd346cddf34ead849706e3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747227615,
      "headline": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know",
      "id": 134460787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=6254788561d9d8281c349457b4313591f319baf9afd346cddf34ead849706e3f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas",
    "summary": "AbbVie (NYSE: ABBV) and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA therapeutics, today announced a collaboration and license option agreement to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology.",
    "url": "https://finnhub.io/api/news?id=fb0fd1da37bea00dd004121c7157af847b9a6c4e5bc2e37846edbf86c7676936",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747227300,
      "headline": "AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas",
      "id": 134460788,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA therapeutics, today announced a collaboration and license option agreement to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology.",
      "url": "https://finnhub.io/api/news?id=fb0fd1da37bea00dd004121c7157af847b9a6c4e5bc2e37846edbf86c7676936"
    }
  },
  {
    "ts": null,
    "headline": "IXJ: Healthcare Sector Dashboard For May",
    "summary": "This article provides a top-down analysis of the healthcare sector using value, quality, and momentum metrics. Read the full analysis here on Seeking Alpha, updated for May 2025.",
    "url": "https://finnhub.io/api/news?id=6034d561f5dd4a27632eead6ab25b5a039e4bdb6720041cd8cd9e718132da992",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747223425,
      "headline": "IXJ: Healthcare Sector Dashboard For May",
      "id": 134437816,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1356518831/image_1356518831.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "This article provides a top-down analysis of the healthcare sector using value, quality, and momentum metrics. Read the full analysis here on Seeking Alpha, updated for May 2025.",
      "url": "https://finnhub.io/api/news?id=6034d561f5dd4a27632eead6ab25b5a039e4bdb6720041cd8cd9e718132da992"
    }
  },
  {
    "ts": null,
    "headline": "Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses",
    "summary": "As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers.",
    "url": "https://finnhub.io/api/news?id=5d1b4933b8f2f350013fdcdf5234ad467178f93a9f926311b7b168c431989ec6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747193465,
      "headline": "Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses",
      "id": 134460789,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers.",
      "url": "https://finnhub.io/api/news?id=5d1b4933b8f2f350013fdcdf5234ad467178f93a9f926311b7b168c431989ec6"
    }
  }
]